(S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl} -methanesulfonamide: A potent, nonsteroidal, functional antagonist of the mineralocorticoid receptor

Journal of Medicinal Chemistry

Volumn 50, Issue 26, 2007, Pages 6443-6445

  Bell, Michael G ^a   Gernert, Douglas L ^a   Grese, Timothy A ^a   Belvo, Matthew D ^a   Borromeo, Peter S ^a   Kelley, Sally A ^a   Kennedy, Joseph H ^a   Kolis, Stanley P ^a   Lander, Peter A ^a   Richey, Rachel ^a   Sharp, V Scott ^a   Stephenson, Gregory A ^a   Williams, Jeffrey D ^a   Yu, Hannah ^a   Zimmerman, Karen M ^a   Steinberg, Mitchell I ^a   Jadhav, Prabhakar K ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPLERENONE; MESYLIC ACID DERIVATIVE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; N [3 [1 CYCLOPROPYL 1 (2,4 DIFLUOROPHENYL)ETHYL] 1H INDOL 6 YL]METHANESULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DISEASE MODEL; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; GRIGNARD REACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; NONHUMAN; RAT; REACTION ANALYSIS; RECEPTOR AFFINITY; SPRAGUE DAWLEY RAT; STRUCTURE ANALYSIS; X RAY ANALYSIS;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CRYSTALLOGRAPHY, X-RAY; INDOLES; MODELS, MOLECULAR; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MINERALOCORTICOID; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 37348999923     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701186z     Document Type: Article

References (10)

1. Fardella, C.; Miller, W. Annu. Rev. Nutr. 1996, 16, 443.
2. Pitt, B.; Zannad, F.; Remme, W. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New Engl. J. Med. 1999, 341, 709-717.
3. De Gasparo, M.; Whitebread, S. E.; Preiswerk, G.; Jeunemaitre, X.; Corvol, P.; Menard, J. Antialdosterones: Incidence and prevention of sexual side effects. J. Steroid Biochem. 1989, 32 (1B), 223-227.
4. McKelvie, R. S.; Yusuf, S.; Pericak, D.; Avezum, A.; Burns, R. J.; Probstfield, J.; Tsuyuki, R. T.; White, M.; Rouleau, J.; Latini, R.; Maggioni, A.; Young, J.; Pogue, J. Comparison of candesartan, enalapril, and their combination in congestive heart failure, randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study, the RESOLVD pilot study investigators. Circulation 1999, 100 (10), 1056-1064.
5. Whitehead, C; Whitesitt, C. Effect of lipophilic substituents on some biological properties of indoles. J. Med. Chem. 1974, 17, 1296-1304.
6. Neel, D. A.; Brown, M. L.; Lander, P. A.; Grese, T. A.; Defauw, J. M.; Doti, R. A.; Fields, T.; Kelley, S. A.; Smith, S.; Zimmerman, K. M.; Steinberg, M. I.; Jadhav, P. K. 3,3-Bisaryloxindoles as mineralocorticoid receptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15 (10), 2553-2557.
7. Bell, M. G.; Gavardinas, K.; Gernert, D. L.; Grese, T. A.; Jadhav, P. K.; Lander, P. A.; Steinberg, M. I. Preparation of indole derived modulators of steroid hormone nuclear receptors. PCT Int. Appl., WO 2004067529, Al 20040812, 2004; p 243.
8. Hui, R.; Grose, J. H.; Lebel, M.; Falardeau, P. Prostanoids and aldosterone-induced mild experimental hypertension in rats. Hypertension 1990, 15 (2), 198-203.
9. 13C NMR Spectroscopy; Kennedy, J. H., Reutzel-Edens, S. M., Sharp, V. S., Eds.; HPLC 2006 International Symposium of Liquid Chromatography and Related Techniques; San Francisco, CA, June, 2006.
10. Sharp, V. S.; Kennedy, J. H.; Belvo, M. D.; Williams, J. D.; Risley, D. Enantiomeric separation of mineralocorticoid receptor (hMR) antagonists using the chiracel OJ-H HPLC column with novel polar cosolvent eluent systems. Chirality 2006, 18, 437-445.